Compare RES & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | XERS |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1995 | 2021 |
| Metric | RES | XERS |
|---|---|---|
| Price | $5.73 | $7.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.64 | ★ $10.83 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $41,919,000,000.00 | $49,590,000.00 |
| Revenue This Year | $3.29 | $34.37 |
| Revenue Next Year | $4.05 | $22.86 |
| P/E Ratio | ★ $45.40 | $720.00 |
| Revenue Growth | ★ 2216.21 | 142.67 |
| 52 Week Low | $4.18 | $4.52 |
| 52 Week High | $8.16 | $10.08 |
| Indicator | RES | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 28.17 | 73.45 |
| Support Level | $5.19 | $7.27 |
| Resistance Level | $5.76 | $8.43 |
| Average True Range (ATR) | 0.32 | 0.26 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 5.52 | 95.56 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.